Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 2Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 208Multiple Endocrine Neoplasia Type 1 130Thyroid Cancer, Papillary 78Pituitary Neoplasms 70Thyroid Neoplasms 59Pheochromocytoma 55Carcinoma, Neuroendocrine 49Neoplasms 48Carcinoid Tumor 48Carcinoma, Medullary 35Adrenocortical Carcinoma 35Adenocarcinoma, Follicular 34Pancreatic Neoplasms 33Thyroid Carcinoma, Anaplastic 30Neoplasm Metastasis 27Carcinoma, Non-Small-Cell Lung 27Insulinoma 26Breast Neoplasms 25Paraganglioma 24Melanoma 23Colorectal Neoplasms 23Colonic Neoplasms 23Carcinoma, Renal Cell 23Adenoma, Islet Cell 23Somatostatinoma 22Adrenal Gland Neoplasms 22Sarcoma 21Carcinoma, Islet Cell 21Prostatic Neoplasms 20Glucagonoma 19

Interventions

copanlisib 1Vemurafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid cancer, follicular × Endocrine × Clear all
NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡